Ramelteon, a selective MT1/MT2 receptor agonist, suppresses the proliferation and invasiveness of endometrial cancer cells

A systematic review and meta-analysis of physical activity and endometrial cancer risk

(2015) Daniela Schmid et al.   EUROPEAN JOURNAL OF EPIDEMIOLOGY

F-box protein FBXW7 inhibits cancer metastasis in a non-cell-autonomous manner

(2015) Kanae Yumimoto et al.   JOURNAL OF CLINICAL INVESTIGATION

Functional role of CD44v-xCT system in the development of spasmolytic polypeptide-expressing metaplasia

(2013) Takeyuki Wada et al.   CANCER SCIENCE

Expression of melatonin receptor MT1 in cells of human invasive ductal breast carcinoma

(2012) Karolina Jablonska et al.   JOURNAL OF PINEAL RESEARCH

Basic Mechanisms Involved in the Anti-Cancer Effects of Melatonin

(2011) M. D. Mediavilla et al.   CURRENT MEDICINAL CHEMISTRY

Gender-related invasion differences associated with mRNA expression levels of melatonin membrane receptors in colorectal cancer

(2011) Josefa León et al.   MOLECULAR CARCINOGENESIS

Pharmacology of Ramelteon, a Selective MT1/MT2Receptor Agonist: A Novel Therapeutic Drug for Sleep Disorders

(2009) Masaomi Miyamoto   CNS Neuroscience & Therapeutics

Molecular Mechanisms of Melatonin Anticancer Effects

(2009) Steven M. Hill et al.   INTEGRATIVE CANCER THERAPIES

Expression of melatonin receptor (MT1) and interaction between melatonin and estrogen in endometrial cancer cell line

(2008) Mari Watanabe et al.   JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH